The potential therapeutic role of NRG/ErbB signaling in HF emerged from clinical safety data indicating an increased risk of HF and systolic dysfunction in patients with breast cancer being treated with trastuzumab (a humanized monoclonal antibody targeting ErbB2)[210,211]. This evidence concerns the gene ERBB2 and hydrops fetalis.